Detection and Characterization of Pulmonary Disease by Transthoracic Doppler (TTD)


The study seeks to characterize data obtained from patients with a variety of lung diseases using ultrasound Doppler signals obtained from lung tissue. A standard ultrasound device in a Doppler mode is placed on the chest wall and the unique software the investigators have developed analyzes the signals reflected from within the lung. On the basis of of pilot studies performed previously the investigators expect to receive different signals from different diseases that will enable diagnosis of different lung diseases.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: October 2013

Clinical Trial Outcome Measures

Primary Measures

  • Characterization of Lung Doppler signals obtained from different lung diseases.
    • Time Frame: 1 year

Participating in This Clinical Trial

Inclusion Criteria

  • Able and willing to provide informed consent
  • Age 18 years or older
  • Clinic and hospital records including additional background medical data such as results of echocardiograms, cardiac catheterization pathology reports etc., available and accessible.
  • Evaluation by a physician who determines that a High Resolution Computed Tomography (HRCT) of the Thorax and pulmonary function tests, including spirometry, lung volumes and diffusion capacity, are indicated as part of the standard clinical care.
  • If full lung function tests are normal imaging with a regular chest x-ray is sufficient.
  • Study Population – subjects will be grouped based on the following criteria after obtaining pulmonary function tests and HRCT of the thorax

1. COPD based on clinical assessment and spirometry showing airflow limitation i.e., (FEV1/FVC < 0.70).

2. Interstitial lung disease (ILD) diagnosed by HRCT.

3. Control subjects presenting with pulmonary complaints evaluated by full PFTs (spirometry, lung volume and DLCO) and a chest x-ray and/or HRCT , all found to be within normal limits, .

Exclusion Criteria

  • Primary or metastatic lung cancer.
  • Acute pneumonia.
  • Concomitant or previous diagnosis of Bronchial Asthma.
  • Patients with severe chest wall deformity
  • Decompensated heart failure or volume overload.
  • Significant right-sided pleural effusion.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Echosense Ltd.
  • Collaborator
    • University of Maryland, College Park
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.